It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileNVCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while NVCR’s TA Score has 4 bullish TA indicator(s).
ALGN (@Pharmaceuticals: Other) experienced а -8.46% price change this week, while NVCR (@Medical/Nursing Services) price change was -3.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.04%. For the same industry, the average monthly price growth was -0.04%, and the average quarterly price growth was +8.70%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.85%. For the same industry, the average monthly price growth was -7.89%, and the average quarterly price growth was +10.85%.
ALGN is expected to report earnings on Feb 04, 2026.
NVCR is expected to report earnings on Feb 19, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-4.85% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ALGN | NVCR | ALGN / NVCR | |
| Capitalization | 9.49B | 1.28B | 741% |
| EBITDA | 793M | -113.5M | -699% |
| Gain YTD | -36.564 | -61.611 | 59% |
| P/E Ratio | 25.63 | N/A | - |
| Revenue | 3.97B | 642M | 618% |
| Total Cash | 901M | 1.03B | 87% |
| Total Debt | 123M | 798M | 15% |
ALGN | NVCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 63 | 96 | |
PRICE GROWTH RATING 1..100 | 63 | 84 | |
P/E GROWTH RATING 1..100 | 82 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (76) in the Medical Specialties industry is in the same range as NVCR (100). This means that ALGN’s stock grew similarly to NVCR’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVCR (100). This means that ALGN’s stock grew similarly to NVCR’s over the last 12 months.
ALGN's SMR Rating (63) in the Medical Specialties industry is somewhat better than the same rating for NVCR (96). This means that ALGN’s stock grew somewhat faster than NVCR’s over the last 12 months.
ALGN's Price Growth Rating (63) in the Medical Specialties industry is in the same range as NVCR (84). This means that ALGN’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (8) in the Medical Specialties industry is significantly better than the same rating for ALGN (82). This means that NVCR’s stock grew significantly faster than ALGN’s over the last 12 months.
| ALGN | NVCR | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 85% |
| Advances ODDS (%) | 9 days ago 73% | 9 days ago 75% |
| Declines ODDS (%) | 2 days ago 73% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 66% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 86% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HTAX | 24.57 | 0.09 | +0.36% |
| Macquarie National High-Yield Municipal Bond ETF | |||
| AGRW | 30.10 | N/A | N/A |
| Allspring LT Large Growth ETF | |||
| QVOY | 27.78 | -0.10 | -0.36% |
| Q3 All-Season Active Rotation ETF | |||
| NJUL | 70.76 | -0.29 | -0.41% |
| Innovator Nasdaq-100 Power Bfr ETF Jul | |||
| CHAT | 59.04 | -0.75 | -1.25% |
| Roundhill Generative AI & Technology ETF | |||
A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with BAX. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then BAX could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | -0.26% | ||
| BAX - ALGN | 65% Loosely correlated | +2.14% | ||
| NVST - ALGN | 57% Loosely correlated | +0.10% | ||
| XRAY - ALGN | 53% Loosely correlated | -1.25% | ||
| LUNG - ALGN | 52% Loosely correlated | +3.31% | ||
| SAUHY - ALGN | 49% Loosely correlated | -2.53% | ||
More | ||||
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with BLFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | +1.51% | ||
| BLFS - NVCR | 39% Loosely correlated | +0.08% | ||
| ALGN - NVCR | 38% Loosely correlated | -0.26% | ||
| AZTA - NVCR | 38% Loosely correlated | +0.20% | ||
| TWST - NVCR | 37% Loosely correlated | -1.74% | ||
| ENOV - NVCR | 36% Loosely correlated | -0.21% | ||
More | ||||